{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T22:30:33Z","timestamp":1761863433744},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2015,3,14]],"date-time":"2015-03-14T00:00:00Z","timestamp":1426291200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2015,11]]},"DOI":"10.1007\/s00432-015-1949-7","type":"journal-article","created":{"date-parts":[[2015,3,13]],"date-time":"2015-03-13T09:53:23Z","timestamp":1426240403000},"page":"1899-1907","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["A bispecific antibody directly induces lymphoma cell death by simultaneously targeting CD20 and HLA-DR"],"prefix":"10.1007","volume":"141","author":[{"given":"Jing","family":"Zeng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ran","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinjing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Fang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,3,14]]},"reference":[{"key":"1949_CR1","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1038\/nbt1137","volume":"23","author":"GP Adams","year":"2005","unstructured":"Adams GP, Weiner LM (2005) Monoclonal antibody therapy of cancer. Nat Biotechnol 23:1147\u20131157","journal-title":"Nat Biotechnol"},{"key":"1949_CR2","first-page":"776","volume":"9","author":"AS Advani","year":"2011","unstructured":"Advani AS (2011) Blinatumomab: a novel agent to treat minimal residual disease in patients with acute lymphoblastic leukemia. Clin Adv Hematol Oncol 9:776\u2013777","journal-title":"Clin Adv Hematol Oncol"},{"key":"1949_CR3","doi-asserted-by":"crossref","first-page":"4519","DOI":"10.1182\/blood-2010-07-296913","volume":"117","author":"W Alduaij","year":"2011","unstructured":"Alduaij W, Ivanov A, Honeychurch J, Cheadle EJ, Potluri S, Lim SH et al (2011) Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies. Blood 117:4519\u20134529","journal-title":"Blood"},{"key":"1949_CR4","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1182\/blood.V94.8.2562.420k20_2562_2568","volume":"94","author":"MA Arndt","year":"1999","unstructured":"Arndt MA, Krauss J, Kipriyanov SM, Pfreundschuh M, Little M (1999) A bispecific diabody that mediates natural killer cell cytotoxicity against xenotransplantated human Hodgkin\u2019s tumors. Blood 94:2562\u20132568","journal-title":"Blood"},{"key":"1949_CR5","doi-asserted-by":"crossref","first-page":"562","DOI":"10.4049\/jimmunol.142.2.562","volume":"142","author":"S Braesch-Andersen","year":"1989","unstructured":"Braesch-Andersen S, Paulie S, Koho H, Nika H, Aspenstrom P, Perlmann P (1989) Biochemical characteristics and partial amino acid sequence of the receptor-like human B cell and carcinoma antigen CDw40. J Immunol 142:562\u2013567","journal-title":"J Immunol"},{"key":"1949_CR6","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1172\/JCI111318","volume":"73","author":"HE Broxmeyer","year":"1984","unstructured":"Broxmeyer HE, Juliano L, Lu L, Platzer E, Dupont B (1984) HLA-DR human histocompatibility leukocyte antigens-restricted lymphocyte-monocyte interactions in the release from monocytes of acidic isoferritins that suppress hematopoietic progenitor cells. J Clin Invest 73:939\u2013953","journal-title":"J Clin Invest"},{"key":"1949_CR7","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/35101072","volume":"1","author":"P Carter","year":"2001","unstructured":"Carter P (2001) Improving the efficacy of antibody-based cancer therapies. Nat Rev Cancer 1:118\u2013129","journal-title":"Nat Rev Cancer"},{"key":"1949_CR8","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1056\/NEJMra0708875","volume":"359","author":"BD Cheson","year":"2008","unstructured":"Cheson BD, Leonard JP (2008) Monoclonal antibody therapy for B-cell non-Hodgkin\u2019s lymphoma. N Engl J Med 359:613\u2013626","journal-title":"N Engl J Med"},{"key":"1949_CR9","first-page":"581","volume":"8","author":"S Coral","year":"1997","unstructured":"Coral S, Pucillo C, Leonardi A, Fonsatti E, Altomonte M, Maio M (1997) Triggering of HLA-DR antigens differentially modulates tumor necrosis factor alpha release by B cells at distinct stage of maturation. Cell Growth Differ 8:581\u2013588","journal-title":"Cell Growth Differ"},{"key":"1949_CR10","doi-asserted-by":"crossref","first-page":"4711","DOI":"10.1200\/JCO.2004.04.020","volume":"22","author":"MS Czuczman","year":"2004","unstructured":"Czuczman MS, Weaver R, Alkuzweny B, Berlfein J, Grillo-Lopez AJ (2004) Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin\u2019s lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up. J Clin Oncol 22:4711\u20134716","journal-title":"J Clin Oncol"},{"key":"1949_CR11","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/S0093-7754(03)00252-5","volume":"30","author":"M Dechant","year":"2003","unstructured":"Dechant M, Bruenke J, Valerius T (2003) HLA class II antibodies in the treatment of hematologic malignancies. Semin Oncol 30:465\u2013475","journal-title":"Semin Oncol"},{"key":"1949_CR12","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1089\/cbr.1997.12.177","volume":"12","author":"A Demidem","year":"1997","unstructured":"Demidem A, Lam T, Alas S, Hariharan K, Hanna N, Bonavida B (1997) Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs. Cancer Biother Radiopharm 12:177\u2013186","journal-title":"Cancer Biother Radiopharm"},{"key":"1949_CR13","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/978-1-61779-921-1_9","volume":"899","author":"E DiGiammarino","year":"2012","unstructured":"DiGiammarino E, Ghayur T, Liu J (2012) Design and generation of DVD-Ig molecules for dual-specific targeting. Methods Mol Biol 899:145\u2013156","journal-title":"Methods Mol Biol"},{"key":"1949_CR14","doi-asserted-by":"crossref","first-page":"4115","DOI":"10.4049\/jimmunol.163.8.4115","volume":"163","author":"B Drenou","year":"1999","unstructured":"Drenou B, Blancheteau V, Burgess DH, Fauchet R, Charron DJ, Mooney NA (1999) A caspase-independent pathway of MHC class II antigen-mediated apoptosis of human B lymphocytes. J Immunol 163:4115\u20134124","journal-title":"J Immunol"},{"key":"1949_CR15","doi-asserted-by":"crossref","first-page":"3823","DOI":"10.1016\/j.molimm.2007.06.151","volume":"44","author":"MJ Glennie","year":"2007","unstructured":"Glennie MJ, French RR, Cragg MS, Taylor RP (2007) Mechanisms of killing by anti-CD20 monoclonal antibodies. Mol Immunol 44:3823\u20133837","journal-title":"Mol Immunol"},{"key":"1949_CR16","doi-asserted-by":"crossref","first-page":"5126","DOI":"10.1182\/blood-2010-03-270256","volume":"115","author":"E Hertlein","year":"2010","unstructured":"Hertlein E, Byrd JC (2010) HLA-DR meets ERK. Blood 115:5126\u20135127","journal-title":"Blood"},{"key":"1949_CR17","doi-asserted-by":"crossref","first-page":"63","DOI":"10.3389\/fonc.2014.00063","volume":"4","author":"LM Hoffman","year":"2014","unstructured":"Hoffman LM, Gore L (2014) Blinatumomab, a bi-specific anti-CD19\/CD3 BiTE antibody for the treatment of acute lymphoblastic leukemia: perspectives and current pediatric applications. Front Oncol 4:63","journal-title":"Front Oncol"},{"key":"1949_CR18","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1006\/bcmd.2000.0287","volume":"26","author":"JK Hofmeister","year":"2000","unstructured":"Hofmeister JK, Cooney D, Coggeshall KM (2000) Clustered CD20 induced apoptosis: src-family kinase, the proximal regulator of tyrosine phosphorylation, calcium influx, and caspase 3-dependent apoptosis. Blood Cells Mol Dis 26:133\u2013143","journal-title":"Blood Cells Mol Dis"},{"key":"1949_CR19","doi-asserted-by":"crossref","first-page":"3523","DOI":"10.1182\/blood-2011-12-395541","volume":"119","author":"J Honeychurch","year":"2012","unstructured":"Honeychurch J, Alduaij W, Azizyan M, Cheadle EJ, Pelicano H, Ivanov A et al (2012) Antibody-induced nonapoptotic cell death in human lymphoma and leukemia cells is mediated through a novel reactive oxygen species-dependent pathway. Blood 119:3523\u20133533","journal-title":"Blood"},{"key":"1949_CR20","first-page":"2143","volume":"119","author":"A Ivanov","year":"2009","unstructured":"Ivanov A, Beers SA, Walshe CA, Honeychurch J, Alduaij W, Cox KL et al (2009) Monoclonal antibodies directed to CD20 and HLA-DR can elicit homotypic adhesion followed by lysosome-mediated cell death in human lymphoma and leukemia cells. J Clin Invest 119:2143\u20132159","journal-title":"J Clin Invest"},{"key":"1949_CR21","doi-asserted-by":"crossref","first-page":"6730","DOI":"10.1158\/1078-0432.CCR-13-0081","volume":"19","author":"Y Kienast","year":"2013","unstructured":"Kienast Y, Klein C, Scheuer W, Raemsch R, Lorenzon E, Bernicke D et al (2013) Ang-2-VEGF-A CrossMab, a novel bispecific human IgG1 antibody blocking VEGF-A and Ang-2 functions simultaneously, mediates potent antitumor, antiangiogenic, and antimetastatic efficacy. Clin Cancer Res 19:6730\u20136740","journal-title":"Clin Cancer Res"},{"key":"1949_CR22","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1002\/ijc.1366","volume":"93","author":"SA Kostelny","year":"2001","unstructured":"Kostelny SA, Link BK, Tso JY, Vasquez M, Jorgensen BH, Wang H et al (2001) Humanization and characterization of the anti-HLA-DR antibody 1D10. Int J Cancer 93:556\u2013565","journal-title":"Int J Cancer"},{"key":"1949_CR23","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.canlet.2010.08.011","volume":"299","author":"G Kou","year":"2010","unstructured":"Kou G, Shi J, Chen L, Zhang D, Hou S, Zhao L et al (2010) A bispecific antibody effectively inhibits tumor growth and metastasis by simultaneous blocking vascular endothelial growth factor A and osteopontin. Cancer Lett 299:130\u2013136","journal-title":"Cancer Lett"},{"key":"1949_CR24","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1093\/protein\/gzs040","volume":"25","author":"SR Kuo","year":"2012","unstructured":"Kuo SR, Wong L, Liu JS (2012) Engineering a CD123\u00a0\u00d7\u00a0CD3 bispecific scFv immunofusion for the treatment of leukemia and elimination of leukemia stem cells. Protein Eng Des Sel 25:561\u2013569","journal-title":"Protein Eng Des Sel"},{"key":"1949_CR25","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.bbmt.2004.11.017","volume":"11","author":"N Laudi","year":"2005","unstructured":"Laudi N, Arora M, Burns LJ, Miller JS, McGlave PB, Barker JN et al (2005) Long-term follow-up after autologous hematopoietic stem cell transplantation for low-grade non-Hodgkin lymphoma. Biol Blood Marrow Transplant 11:129\u2013135","journal-title":"Biol Blood Marrow Transplant"},{"key":"1949_CR26","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1002\/(SICI)1521-4141(199901)29:01<65::AID-IMMU65>3.0.CO;2-E","volume":"29","author":"C Leveille","year":"1999","unstructured":"Leveille C, AL-D R, Mourad W (1999) CD20 is physically and functionally coupled to MHC class II and CD40 on human B cell lines. Eur J Immunol 29:65\u201374","journal-title":"Eur J Immunol"},{"key":"1949_CR27","doi-asserted-by":"crossref","first-page":"2282","DOI":"10.1002\/1521-4141(200208)32:8<2282::AID-IMMU2282>3.0.CO;2-M","volume":"32","author":"C Leveille","year":"2002","unstructured":"Leveille C, Castaigne JG, Charron D, Al-Daccak R (2002) MHC class II isotype-specific signaling complex on human B cells. Eur J Immunol 32:2282\u20132291","journal-title":"Eur J Immunol"},{"key":"1949_CR28","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1089\/cbr.2004.19.545","volume":"19","author":"C Liu","year":"2004","unstructured":"Liu C, DeNardo G, Tobin E, DeNardo S (2004) Antilymphoma effects of anti-HLA-DR and CD20 monoclonal antibodies (Lym-1 and Rituximab) on human lymphoma cells. Cancer Biother Radiopharm 19:545\u2013561","journal-title":"Cancer Biother Radiopharm"},{"key":"1949_CR29","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1182\/blood.V95.6.2098","volume":"95","author":"A Loffler","year":"2000","unstructured":"Loffler A, Kufer P, Lutterbuse R, Zettl F, Daniel PT, Schwenkenbecher JM et al (2000) A recombinant bispecific single-chain antibody, CD19\u00a0\u00d7\u00a0CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes. Blood 95:2098\u20132103","journal-title":"Blood"},{"key":"1949_CR30","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1084\/jem.172.5.1513","volume":"172","author":"W Mourad","year":"1990","unstructured":"Mourad W, Geha RS, Chatila T (1990) Engagement of major histocompatibility complex class II molecules induces sustained, lymphocyte function-associated molecule 1-dependent cell adhesion. J Exp Med 172:1513\u20131516","journal-title":"J Exp Med"},{"key":"1949_CR31","doi-asserted-by":"crossref","first-page":"89","DOI":"10.2165\/11530960-000000000-00000","volume":"24","author":"D Muller","year":"2010","unstructured":"Muller D, Kontermann RE (2010) Bispecific antibodies for cancer immunotherapy: current perspectives. BioDrugs 24:89\u201398","journal-title":"BioDrugs"},{"key":"1949_CR32","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1111\/j.1600-6143.2006.01288.x","volume":"6","author":"MD Pescovitz","year":"2006","unstructured":"Pescovitz MD (2006) Rituximab, an anti-cd20 monoclonal antibody: history and mechanism of action. Am J Transplant 6:859\u2013866","journal-title":"Am J Transplant"},{"key":"1949_CR33","first-page":"5","volume":"5","author":"CA Portell","year":"2013","unstructured":"Portell CA, Wenzell CM, Advani AS (2013) Clinical and pharmacologic aspects of blinatumomab in the treatment of B-cell acute lymphoblastic leukemia. Clin Pharmacol 5:5\u201311","journal-title":"Clin Pharmacol"},{"key":"1949_CR34","doi-asserted-by":"crossref","first-page":"7600","DOI":"10.1158\/0008-5472.CAN-10-2126","volume":"70","author":"EA Rossi","year":"2010","unstructured":"Rossi EA, Rossi DL, Stein R, Goldenberg DM, Chang CH (2010) A bispecific antibody-IFN\u03b12b immunocytokine targeting CD20 and HLA-DR is highly toxic to human lymphoma and multiple myeloma cells. Cancer Res 70:7600\u20137609","journal-title":"Cancer Res"},{"key":"1949_CR35","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1182\/blood-2011-03-343145","volume":"118","author":"EA Rossi","year":"2011","unstructured":"Rossi EA, Rossi DL, Cardillo TM, Stein R, Goldenberg DM, Chang CH (2011) Preclinical studies on targeted delivery of multiple IFN\u03b12b to HLA-DR in diverse hematologic cancers. Blood 118:1877\u20131884","journal-title":"Blood"},{"key":"1949_CR36","doi-asserted-by":"crossref","first-page":"2","DOI":"10.3390\/antib1010002","volume":"1","author":"ISC Schubert","year":"2012","unstructured":"Schubert ISC, Fey GH (2012) Dual-targeting for the elimination of cancer cells with increased selectivity. Antibodies 1:2\u201318","journal-title":"Antibodies"},{"key":"1949_CR37","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1038\/nrc3236","volume":"12","author":"AM Scott","year":"2012","unstructured":"Scott AM, Wolchok JD, Old LJ (2012) Antibody therapy of cancer. Nat Rev Cancer 12:278\u2013287","journal-title":"Nat Rev Cancer"},{"key":"1949_CR38","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1097\/CJI.0b013e3181dda225","volume":"33","author":"H Singer","year":"2010","unstructured":"Singer H, Kellner C, Lanig H, Aigner M, Stockmeyer B, Oduncu F et al (2010) Effective elimination of acute myeloid leukemic cells by recombinant bispecific antibody derivatives directed against CD33 and CD16. J Immunother 33:599\u2013608","journal-title":"J Immunother"},{"key":"1949_CR39","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1126\/science.1241145","volume":"341","author":"MX Sliwkowski","year":"2013","unstructured":"Sliwkowski MX, Mellman I (2013) Antibody therapeutics in cancer. Science 341:1192\u20131198","journal-title":"Science"},{"key":"1949_CR40","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1038\/314628a0","volume":"314","author":"UD Staerz","year":"1985","unstructured":"Staerz UD, Kanagawa O, Bevan MJ (1985) Hybrid antibodies can target sites for attack by T cells. Nature 314:628\u2013631","journal-title":"Nature"},{"key":"1949_CR41","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1182\/blood-2006-04-017921","volume":"108","author":"R Stein","year":"2006","unstructured":"Stein R, Qu Z, Chen S, Solis D, Hansen HJ, Goldenberg DM (2006) Characterization of a humanized IgG4 anti-HLA-DR monoclonal antibody that lacks effector cell functions but retains direct antilymphoma activity and increases the potency of rituximab. Blood 108:2736\u20132744","journal-title":"Blood"},{"key":"1949_CR42","doi-asserted-by":"crossref","first-page":"5180","DOI":"10.1182\/blood-2009-06-228288","volume":"115","author":"R Stein","year":"2010","unstructured":"Stein R, Gupta P, Chen X, Cardillo TM, Furman RR, Chen S et al (2010) Therapy of B-cell malignancies by anti-HLA-DR humanized monoclonal antibody, IMMU-114, is mediated through hyperactivation of ERK and JNK MAP kinase signaling pathways. Blood 115:5180\u20135190","journal-title":"Blood"},{"key":"1949_CR43","doi-asserted-by":"crossref","first-page":"273","DOI":"10.3109\/10428194.2010.535182","volume":"52","author":"R Stein","year":"2011","unstructured":"Stein R, Balkman C, Chen S, Rassnick K, McEntee M, Page R et al (2011) Evaluation of anti-human leukocyte antigen-DR monoclonal antibody therapy in spontaneous canine lymphoma. Leuk Lymphoma 52:273\u2013284","journal-title":"Leuk Lymphoma"},{"key":"1949_CR44","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1007\/s00277-004-0897-0","volume":"83","author":"I Takacs","year":"2004","unstructured":"Takacs I, Eros N, Bene I, Bozso F, Tordai L, Karolyi Z et al (2004) Successful treatment of relapse of an intravascular B-cell lymphoma with rituximab-CHOP polychemotherapy. Ann Hematol 83:608\u2013610","journal-title":"Ann Hematol"},{"key":"1949_CR45","doi-asserted-by":"crossref","first-page":"946","DOI":"10.4161\/mabs.26390","volume":"5","author":"W Tan","year":"2013","unstructured":"Tan W, Meng Y, Li H, Chen Y, Han S, Zeng J et al (2013) A bispecific antibody against two different epitopes on hepatitis B surface antigen has potent hepatitis B virus neutralizing activity. MAbs 5:946\u2013955","journal-title":"MAbs"},{"key":"1949_CR46","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1084\/jem.20040119","volume":"199","author":"J Uchida","year":"2004","unstructured":"Uchida J, Hamaguchi Y, Oliver JA, Ravetch JV, Poe JC, Haas KM et al (2004) The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy. J Exp Med 199:1659\u20131669","journal-title":"J Exp Med"},{"key":"1949_CR47","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/S0167-5699(00)01659-5","volume":"21","author":"AB Spriel van","year":"2000","unstructured":"van Spriel AB, van Ojik HH, van De Winkel JG (2000) Immunotherapeutic perspective for bispecific antibodies. Immunol Today 21:391\u2013397","journal-title":"Immunol Today"},{"key":"1949_CR48","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1182\/blood.V79.4.1003.bloodjournal7941003","volume":"79","author":"CM Verfaillie","year":"1992","unstructured":"Verfaillie CM, Miller WJ, Boylan K, McGlave PB (1992) Selection of benign primitive hematopoietic progenitors in chronic myelogenous leukemia on the basis of HLA-DR antigen expression. Blood 79:1003\u20131010","journal-title":"Blood"},{"key":"1949_CR49","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/S0140-6736(09)60251-8","volume":"373","author":"LM Weiner","year":"2009","unstructured":"Weiner LM, Dhodapkar MV, Ferrone S (2009) Monoclonal antibodies for cancer immunotherapy. Lancet 373:1033\u20131040","journal-title":"Lancet"},{"key":"1949_CR50","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1038\/nbt1345","volume":"25","author":"C Wu","year":"2007","unstructured":"Wu C, Ying H, Grinnell C, Bryant S, Miller R, Clabbers A et al (2007) Simultaneous targeting of multiple disease mediators by a dual-variable-domain immunoglobulin. Nat Biotechnol 25:1290\u20131297","journal-title":"Nat Biotechnol"},{"key":"1949_CR51","doi-asserted-by":"crossref","first-page":"339","DOI":"10.4161\/mabs.1.4.8755","volume":"1","author":"C Wu","year":"2009","unstructured":"Wu C, Ying H, Bose S, Miller R, Medina L, Santora L et al (2009) Molecular construction and optimization of anti-human IL-1alpha\/beta dual variable domain immunoglobulin (DVD-Ig) molecules. MAbs 1:339\u2013347","journal-title":"MAbs"},{"key":"1949_CR52","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.jim.2004.11.005","volume":"296","author":"Z Xie","year":"2005","unstructured":"Xie Z, Guo N, Yu M, Hu M, Shen B (2005) A new format of bispecific antibody: highly efficient heterodimerization, expression and tumor cell lysis. J Immunol Methods 296:95\u2013101","journal-title":"J Immunol Methods"},{"issue":"Suppl 4","key":"1949_CR53","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1080\/10428190310001616917","volume":"44","author":"PL Zinzani","year":"2003","unstructured":"Zinzani PL (2003) Traditional treatment approaches in B-cell non-Hodgkin\u2019s lymphoma. Leuk Lymphoma 44(Suppl 4):S6\u201314","journal-title":"Leuk Lymphoma"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-015-1949-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00432-015-1949-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-015-1949-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,8]],"date-time":"2023-08-08T19:36:53Z","timestamp":1691523413000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00432-015-1949-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3,14]]},"references-count":53,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2015,11]]}},"alternative-id":["1949"],"URL":"https:\/\/doi.org\/10.1007\/s00432-015-1949-7","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"value":"0171-5216","type":"print"},{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,3,14]]}}}